LDL oxidized with iron in the presence of homocysteine/cystine at acidic pH has low cytotoxicity despite high lipid peroxidation

Atherosclerosis

Volumn 187, Issue 2, 2006, Pages 292-300

  Pfanzagl, Beatrix ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acidic pH; Copper; Cytotoxicity; Homocysteine; Inducible nitric oxide synthase; Iron; LDL oxidation

Indexed keywords

COPPER COMPLEX; CYSTINE; HOMOCYSTEINE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON COMPLEX; LIPID HYDROPEROXIDE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZING AGENT; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ACETYLATION; ACIDITY; ARTICLE; BLOOD PH; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROPHAGE; MONOCYTE; OXIDATION KINETICS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MODIFICATION;

ACETYLATION; ACIDS; CELL DIFFERENTIATION; CELL LINE; COPPER; CYSTINE; FOAM CELLS; HOMOCYSTEINE; HUMANS; HYDROGEN-ION CONCENTRATION; IRON; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MONOCYTES; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 33745482661     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.09.024     Document Type: Article

References (33)

1. Stocker R., and Keaney J.F.J. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
2. Stadler N., Lindner R.A., and Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24 (2004) 949-954
3. Kuhn H., Heydeck D., Hugou I., and Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 99 (1997) 888-893
4. Morgan J., and Leake D.S. Oxidation of low density lipoprotein by iron or copper at acidic pH. J Lipid Res 36 (1995) 2504-2512
5. Pfanzagl B., Tribl F., Koller E., and Moslinger T. Homocysteine strongly enhances metal-catalyzed LDL oxidation in the presence of cystine and cysteine. Atherosclerosis 168 (2003) 39-48
6. Leake D.S. Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions?. Atherosclerosis 129 (1997) 149-157
7. Durand P., Prost M., Loreau N., Lussier-Cacan S., and Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 81 (2001) 645-672
8. Thambyrajah J., and Townend J.N. Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J 21 (2000) 967-974
9. Steinbrecher U.P., Lougheed M., Kwan W.C., and Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 264 (1989) 15216-15223
10. Colles S.M., Maxson J.M., Carlson S.G., and Chisolm G.M. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. Trends Cardiovasc Med 11 (2001) 131-138
11. Siow R.C., Richards J.P., Pedley K.C., Leake D.S., and Mann G.E. Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. Arterioscler Thromb Vasc Biol 10 (1999) 2387-2394
12. Carpenter K.L., Challis I.R., and Arends M.J. Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma. FEBS Lett 553 (2003) 145-150
13. Yang X., Cai B., Sciacca R.R., and Cannon P.J. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res 74 (1994) 318-328
14. Huang A., Li C., Kao R.L., and Stone W.L. Lipid hydroperoxides inhibit nitric oxide production in RAW264.7 macrophages. Free Radical Biol Med 26 (1999) 526-537
15. Liu S.X., Chen Y., Zhou M., and Wan J. Oxidized cholesterol in oxidized low density lipoprotein may be responsible for the inhibition of LPS-induced nitric oxide production in macrophages. Atherosclerosis 136 (1998) 43-49
16. Patel R.P., Levonen A., Crawford J.H., and Darley-Usmar V.M. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc Res 47 (2000) 465-474
17. Bloodsworth A., O'Donnell V.B., and Freeman B.A. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vasc Biol 20 (2000) 1707-1715
18. White C.R., Brock T.A., Chang L.Y., et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 91 (1994) 1044-1048
19. Buttery L.D., Springall D.R., Chester A.H., et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75 (1996) 77-85
20. Ueland P.M., Mansoor M.A., Guttormsen A.B., et al. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status-a possible element of the extracellular antioxidant defense system. J Nutr 126 (1996) 1281S-1284S
21. Alul R.H., Wood M., Longo J., et al. Vitamin C protects low-density lipoprotein from homocysteine-mediated oxidation. Free Radical Biol Med 34 (2003) 881-891
22. Asmis R., and Wintergerst E.S. Dehydroascorbic acid prevents apoptosis induced by oxidized low-density lipoprotein in human monocyte-derived macrophages. Eur J Biochem 255 (1998) 147-155
23. Philpott N.J., Turner A.J., Scopes J., et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87 (1996) 2244-2251
24. Huh H.Y., Pearce L.M., Yesner J.L., Schindler R.L., and Silverstein R.L. Regulated expression of CD36 during monocyte-tomacrophage differentiation: potential role of CD36 in foam cell formation. Blood 87 (1996) 2020-2028
25. Green L.C., Wagner D.A., Glogowski J., et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
26. Corsetti J.P., Weidner C.H., Cianci J., and Sparks C.E. The labeling of lipoproteins for studies of cellular binding with a fluorescent lipophilic dye. Anal Biochem 195 (1991) 122-128
27. Ylitalo R., Jaakkola O., Lehtolainen P., and Yla-Herttuala S. Metabolism of modified LDL and foam cell formation in murine macrophage-like RAW 264 cells. Life Sci 64 (1999) 1955-1965
28. Tsukamoto K., Kinoshita M., Kojima K., et al. Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages. J Atheroscler Thromb 9 (2002) 57-64
29. Kiener P.A., Rankin B.M., Davis P.M., et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 15 (1995) 990-999
30. Chin J.H., Azhar S., and Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 89 (1992) 10-18
31. Mackman N. How do oxidized phospholipids inhibit LPS signaling?. Arterioscler Thromb Vasc Biol 23 (2003) 1133-1136
32. Miller Y.I., Viriyakosol S., Binder C.J., et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 278 (2003) 1561-1568
33. Dil N., and Qureshi M.A. Involvement of lipopolysaccharide related receptors and nuclear factor kappa B in differential expression of inducible nitric oxide synthase in chicken macrophages from different genetic backgrounds. Vet Immunol Immunopathol 88 (2002) 149-161